Compositions comprising psilocybin, optionally in combination with n-acylethanolamines and uses thereof
AssigneeClearmind Labs Corp.
InventorAdi ZULOFF-SHANI
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to pharmaceutical compositions comprising psilocybin, or a pharmaceutically acceptable salt thereof, and combinations of psilocybin, or a pharmaceutically acceptable salt thereof and an N-acylethanolamine, or a pharmaceutically salt thereof, and at least one pharmaceutically acceptable carrier and/or excipient, and their use in methods of treating alcohol or substance dependence, tobacco, alcohol or substance addiction, mood disorders, personality disorders, neuropsychiatric disorders, headaches, pain, epilepsy, and inflammation, by administrating said compositions to a subject in need thereof in a therapeutically effective amount.
Claims44
A pharmaceutical composition comprising psilocybin, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier and/or excipient.
A method of treating substance dependence or addiction, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising psilocybin or a pharmaceutically acceptable salt thereof.
A method of treating anxiety disorders, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising psilocybin, or a pharmaceutically acceptable salt thereof.
A method of treating depression or depression-like disorders, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising psilocybin, or a pharmaceutically acceptable salt thereof.
A method of treating personality disorders, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising psilocybin, or a pharmaceutically acceptable salt thereof.
A method of treating pain or headaches, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising psilocybin, or a pharmaceutically acceptable salt thereof.
A method of treating epilepsy, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising psilocybin, or a pharmaceutically acceptable salt thereof.
A method of treating inflammation, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising psilocybin, or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising psilocybin or a pharmaceutically acceptable salt thereof, and an N-acylethanolamine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier and/or excipient.
A method of treating substance dependence or addiction, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising psilocybin, or a pharmaceutically acceptable salt thereof, and an N-acylethanolamine, or a pharmaceutically acceptable salt thereof.
A method of treating anxiety disorders, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising psilocybin, or a pharmaceutically acceptable salt thereof, and an N-acylethanolamine, or a pharmaceutically acceptable salt thereof.
A method of treating depression or depression-like disorders, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising psilocybin, or a pharmaceutically acceptable salt thereof, and an N-acylethanolamine, or a pharmaceutically acceptable salt thereof.
A method of treating personality disorders, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising psilocybin, or a pharmaceutically acceptable salt thereof, and an N-acylethanolamine, or a pharmaceutically acceptable salt thereof.
A method of treating pain or headaches, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising psilocybin, or a pharmaceutically acceptable salt thereof, and an N-acylethanolamine, or a pharmaceutically acceptable salt thereof.
A method of treating epilepsy, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising psilocybin, or a pharmaceutically acceptable salt thereof, and an N-acylethanolamine, or a pharmaceutically acceptable salt thereof.
A method of treating inflammation, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising psilocybin, or a pharmaceutically acceptable salt thereof, and an N-acylethanolamine, or a pharmaceutically acceptable salt thereof.
The pharmaceutical composition of any preceding claim, wherein the N-acylethanolamine is selected from the group consisting of N-palmitoylethanolamine (PEA), Me-palmitoylethanolamide (Me-PEA), palmitoylcyclohexamide, palmitoylbutylamide, palmitoylisopropylamide, oleoylethanolamine (OEA), palmitoylisopropylamide (PIA), salts thereof and any combination thereof.
The method of any preceding claim, wherein the N-acylethanolamine is selected from the group consisting of N-palmitoylethanolamine (PEA), Me-palmitoylethanolamide (Me-PEA), palmitoylcyclohexamide, palmitoylbutylamide, palmitoylisopropylamide, oleoylethanolamine (OEA), palmitoylisopropylamide (PIA), salts thereof and any combination thereof.
The pharmaceutical composition of any preceding claim, wherein the N-acylethanolamine is PEA or a pharmaceutically acceptable salt thereof.
The method of any preceding claim, wherein the N-acylethanolamine is PEA or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.